MedTrace Logo

URO-BCG-4 : Bladder Tumors Immunotherapy

NCT00213655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2014-07-31

No results posted yet for this study

Summary

Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.

Conditions

Interventions

BIOLOGICAL

bladder tumor recurrence

bladder tumor recurrence assessed by clinical and biological exams

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Christian PFISTER, MD, PhD · University Hospital, Rouen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2013-05-31
Completion
2013-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00213655 on ClinicalTrials.gov